National Cancer Institute; Notice of Closed Meeting, 42803 [2014-17260]
Download as PDF
Federal Register / Vol. 79, No. 141 / Wednesday, July 23, 2014 / Notices
Place: National Institutes of Health,
Building 31, Room 6C6, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: Craig A. Jordan, Ph.D.,
Director, Division of Extramural Activities
NIDCD, NIH, Room 8345, MSC 9670, 6001
Executive Blvd., Bethesda, MD 20892–9670,
301–496–8693, jordanc@nidcd.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcd.nih.gov/about/Pages/AdvisoryGroups-and-Review-Committees.aspx, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: July 17, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–17261 Filed 7–22–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK4VPTVN1PROD with NOTICES
National Cancer Institute; Notice of
Closed Meeting
[FR Doc. 2014–17260 Filed 7–22–14; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
17:33 Jul 22, 2014
Jkt 232001
Name of Committee: National Cancer
Institute Special Emphasis Panel NCI
Experimental Therapeutics Program (Cycle
17 NExT).
Date: August 22, 2014.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Conference
Room 6C06, Bethesda, MD 20892.
Contact Person: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20892,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Joseph Tomaszewski, Ph.D., Executive
Secretary, Development Experimental
Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44,
Bethesda, MD 20892, (301) 496–6711,
tomaszej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 17, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
VerDate Mar<15>2010
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Announcement of Requirements and
Registration for ‘‘Stories of Basic
Science to Medical Advances’’
Challenge
Authority: 15 U.S.C. 3719.
The National Institute of
General Medical Sciences (NIGMS), one
of the components of the National
Institutes of Health (NIH), announces a
challenge titled ‘‘Stories of Basic
Science to Medical Advances.’’ This
Challenge aims to track medical
advances stemming from NIGMSsupported basic science.
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
42803
Submission Period: July 21,
2014—October 20, 2014.
Judging Period: October 21, 2014—
November 20, 2014.
Winners announced: 14 days after
judging is complete.
FOR FURTHER INFORMATION CONTACT:
Darren Sledjeski, Ph.D. 301–594–0943,
nigms_challenges@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
mission of NIGMS is to support basic,
non-disease-targeted research that
increases understanding of life
processes and lays the foundation for
advances in disease diagnosis,
treatment, and prevention. NIGMSfunded researchers seek to answer
important scientific questions to
increase our knowledge about the
mechanisms and pathways involved in
diseases and develop new tools and
techniques that have medical
applications. NIGMS’ strategic plan
states that one of its goals is to ‘‘advance
awareness and understanding of the
basic biomedical research enterprise,
including its value, requirements, and
potential impact.’’ Accomplishing this
goal, however, can be difficult because
the path between basic discoveries and
their applications is often long, and the
connections can be hard to track.
In addition to tracking the medical
advances stemming from NIGMSsupported science, the Challenge is also
intended to attract more interest and
attention to the basic science research
funded by NIGMS; stimulate innovation
by acknowledging the key role that
NIGMS funded research plays in laying
the foundation for advances in disease
diagnosis, treatment and prevention;
and advance the statutory purpose of
NIGMS to ‘‘conduct and support
research and health information
dissemination with respect to general or
basic medical sciences and related
natural and behavioral sciences which
have significance for two or more other
national research institutes or are
outside the general area of responsibility
of any other national research institute.’’
42 U.S.C. 285k.
Subject of Challenge: NIH seeks the
public’s help in capturing NIGMS’
progress toward its strategic goal to
‘‘advance awareness and understanding
of the basic biomedical research
enterprise, including its value,
requirements, and potential impact.’’
The goal of the Challenge is to identify
past advances that are serving (or have
served) to improve human health and
well-being but not ongoing studies that
may, in the future, have a major impact.
NIGMS will use these examples to help
inform the historical context of
scientific breakthroughs and NIGMS’
DATES:
E:\FR\FM\23JYN1.SGM
23JYN1
Agencies
[Federal Register Volume 79, Number 141 (Wednesday, July 23, 2014)]
[Notices]
[Page 42803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-17260]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel NCI Experimental Therapeutics Program (Cycle 17 NExT).
Date: August 22, 2014.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Conference Room 6C06, Bethesda, MD 20892.
Contact Person: Barbara Mroczkowski, Ph.D., Executive Secretary,
Discovery Experimental Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892,
(301) 496-4291, mroczkoskib@mail.nih.gov.
Joseph Tomaszewski, Ph.D., Executive Secretary, Development
Experimental Therapeutics Program, National Cancer Institute, NIH,
31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496-6711,
tomaszej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 17, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-17260 Filed 7-22-14; 8:45 am]
BILLING CODE 4140-01-P